Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Entrega de Alimentos a Domicilio para el Manejo de la Diabetes en Pacientes de Clínicas Rurales

21 de agosto de 2026 actualizado por: University of Arkansas

Nuestro objetivo a largo plazo es transformar la gestión de T2DM de los residentes rurales. El objetivo de este estudio es determinar la efectividad de una intervención que sea escalable y sostenible y promueva la adherencia del paciente al mitigar las dificultades de los participantes rurales con inseguridad alimentaria asociadas con la finalización de las intervenciones existentes. Nuestros objetivos específicos son:

  1. Compare la eficacia de la Intervención de entrega de alimentos saludables (HFDI) más la atención estándar y la atención estándar sola para mejorar los resultados relacionados con la diabetes entre los pacientes rurales con inseguridad alimentaria con DM2. Hipótesis: en comparación con la atención estándar sola, los pacientes que reciben HFDI más atención estándar demostrarán una mejora: el control glucémico H1 medido por HbA1c; factores de riesgo cardiometabólico H2: presión arterial, glucosa en ayunas, lípidos en ayunas e IMC; H3 autocuidado: autoeficacia, adherencia a conductas de autocuidado y adherencia a la medicación; Resultados centrados en el paciente H4: angustia relacionada con la diabetes, calidad de vida relacionada con la diabetes y complicaciones relacionadas con la diabetes.
  2. Compare la eficacia del HFDI más la atención estándar y la atención estándar sola para mejorar la calidad de la dieta entre los pacientes rurales con inseguridad alimentaria con DM2. Hipótesis: En comparación con la atención estándar sola, los pacientes que reciben el HFDI más la atención estándar demostrarán mejores: puntajes del índice de alimentación saludable H1 2015 (HEI-2015); Consumo de frutas y verduras H2.
  3. Compare la rentabilidad para comprender HFDI más los costos de atención estándar en relación con los resultados en relación con la atención estándar sola. Hipótesis: El HFDI será rentable en función del costo tradicional por año de vida adicional ajustado por calidad ganado.

Descripción general del estudio

Descripción detallada

Type 2 diabetes mellitus (T2DM) is a growing public health concern affecting 37.3 million people (11.3%) in the United States (US). At the same time, 13.5 million (10.2%) US households experience food insecurity. People living in rural areas are particularly challenged by the intersection of food insecurity and T2DM - both food insecurity and T2DM prevalence in rural areas are higher than metropolitan areas. Arkansas has the sixth highest proportion of rural population (44.5%) of all US states, with rates of food insecurity and T2DM of 14.7% and 12.5%, respectively. Rurality and food insecurity are associated with social determinants of health that impede diabetes management (e.g., limited transportation, longer distance to healthcare clinics, lack of access to healthy food options). People experiencing food insecurity have poor diet quality (e.g., high intake of sugar-sweetened beverages and red/processed meat, low intake of fruits and vegetables), which is a key risk factor for unmanaged T2DM. Unmanaged T2DM can lead to increased risk of serious complications. Improved diet quality is a crucial factor to enhance T2DM management. Millions of people with T2DM experiencing food insecurity turn to food pantries for food; however, food pantries are not a long-term solution to improve health for rural people with T2DM experiencing food insecurity. Certified Diabetes Care and Education Specialists (CDCES; i.e., diabetes educators) have expertise in working with patients to instill knowledge and skills necessary to live an active and healthy lifestyle with T2DM.

This study used a two-arm randomized controlled comparative effectiveness design to compare the effectiveness of a Healthy Food Delivery Intervention (HFDI) plus a consultation with a CDCES Consultation Only in improving diabetes-related outcomes among rural people with T2DM experiencing food insecurity. We hypothesized HFDI to be comparatively more effective in improving HbA1c and other outcomes for rural people with T2DM experiencing food insecurity.

The primary outcome was change in hemoglobin A1c (HbA1c) between baseline and post-intervention. Secondary outcomes included diet quality (Healthy Eating Index-2015 and Veggie meter scores), body mass index, blood pressure, lipids, glucose, diabetes management self-efficacy and diabetes-related distress. We also examined the duration of treatment effects by comparing outcomes at 6 months post-intervention and 12 months post-intervention.

Participants were randomly assigned to either the HFDI arm or the CDCES Consultation Only arm. Participants randomized to the CDCES Consultation Only study arm received the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a CDCES and a food pantry resource guide specific to their community. In addition to standard of care and the CDCES consultation, participants randomized to the HFDI arm received weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total). Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.

Participants were initially recruited only from family medicine clinics within the University of Arkansas for Medical Sciences (UAMS) network that serve the highest percentage of rural patients with T2DM. Additional clinics and Federally Qualified Health Centers were added as recruitment sites in order to meet study recruitment goals.

Inclusion criteria included: 1) 18 years of age or older; 2) food insecure (Hunger Vital Sign™ 2-item screener); 3) HbA1c ≥ 6.5%; 4) speak English or Spanish; and 5) live at a rural address. Note: the food insecurity and rural residence criteria were removed during the course of the study in order to meet study recruitment goals.

Exclusion criteria included: 1) having conditions making it unlikely the participant will be able to follow the protocol, such as terminal illness, severe mental illness, severely impaired vision or hearing, eating disorder, or plans to move out of the geographic region; 2) pregnant; 3) only one adult with T2DM per household was allowed to enroll.

Investigators worked with clinical stakeholders at each clinic site to ensure the study was integrated into existing workflows. Study flyers were placed throughout the clinics, in the exam rooms, and in the clinic waiting areas. All clinics had electronic health record systems that were queried monthly for recruitment. Research coordinators at each clinic site identified potential participants by reviewing monthly patient queries and daily clinic schedules. The research coordinators provided study information to potential participants in a pre-visit call or during the clinical visit. If the patient was interested, the research coordinator scheduled a 30-minute meeting to discuss the study and conduct eligibility screening in a private room in the clinic. Research staff were trained to flag potential participants that may not meet eligibility, which were then sent to the study physician for medical determination. Those deemed eligible to participate reviewed study information with the research coordinator, were given the chance to ask questions, and signed an informed consent. All recruitment and consent information was available in English and Spanish.

Randomization was conducted by the study biostatistician, who had no interactions with potential participants and no supervisory role with study staff responsible for recruiting, consent, and intervention processes. Stratified random assignment using permuted blocks of size 2, 4, and 6 was used to randomize participants 1:1 to the treatment arms using lists created with the blockrand R package. Strata of participant sex, level of T2DM control (6.5-9.0%; >9.0%), and age group (18-64; 65+ years) were used to ensure that similar numbers within each characteristic are assigned 1:1 to the treatment arms.

Data collection occurred in-person at the clinic from which participants were recruited, co-occurring with participants' primary care provider visits when possible. Biometric and survey measure outcomes were collected at baseline (pre-intervention), immediate post-intervention (approximately 12 weeks after baseline), 6 months post-intervention, and 12 months post-intervention.

Tipo de estudio

Intervencionista

Inscripción (Actual)

416

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arkansas
      • Batesville, Arkansas, Estados Unidos, 72501
        • UAMS - North Central
      • Corning, Arkansas, Estados Unidos, 72422
        • Pocahontas Medical Center
      • Eureka Springs, Arkansas, Estados Unidos, 72632
        • Washington Regional Medical Center
      • Fayetteville, Arkansas, Estados Unidos, 72703
        • Washington Regional Medical Center
      • Fayetteville, Arkansas, Estados Unidos, 72703
        • UAMS - Northwest
      • Fort Smith, Arkansas, Estados Unidos, 72901
        • UAMS - West
      • Harrison, Arkansas, Estados Unidos, 72601
        • Washington Regional Medical Center
      • Helena, Arkansas, Estados Unidos, 72390
        • UAMS - East
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • UAMS - Northeast
      • Magnolia, Arkansas, Estados Unidos, 71753
        • UAMS - South
      • Marianna, Arkansas, Estados Unidos, 72360
        • Lee County Cooperative Clinic
      • Marshall, Arkansas, Estados Unidos, 72650
        • Boston Mountain Rural Health Center
      • Pocahontas, Arkansas, Estados Unidos, 72455
        • Pocahontas Medical Clinic

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Descripción

Criterios de inclusión:

  • 18 años de edad o más
  • reportar inseguridad alimentaria
  • informe T2D (confirmado por tener una HbA1c igual o superior a 6.5 en la recopilación de datos inicial inmediatamente después del consentimiento)
  • Habla ingles o español
  • Actualmente vive en una dirección rural

Criterio de exclusión:

  • condiciones que hacen que sea poco probable que el participante pueda seguir el protocolo, como una enfermedad terminal, una enfermedad mental grave, una discapacidad visual o auditiva grave, un trastorno alimentario o planes para mudarse fuera de la región geográfica
  • Embarazada

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: CDCES Consultation Only
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
Experimental: Healthy Food Delivery Intervention
In addition to standard of care and the CDCES consultation, participants randomized to the Healthy Food Delivery arm receive weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).
Participants randomized to the Healthy Food Delivery Intervention receive standard of care, a CDCES Consultation, food pantry resource guide, and weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Hemoglobin A1c (HbA1c)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Finger stick blood collection will be used to test HbA1c using a Siemens DCA Vantage analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diet Quality: Healthy Eating Index-2015 Score
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks)
Diet quality was assessed with a 24-hour dietary recall interview using the Nutrition Data System for Research (NDSR) software. The Healthy Eating Index-2015 (HEI) was applied to the dietary recall data to measure the extent that dietary intake among participants met the Dietary Guidelines for Americans 2015-2020 recommendations. HEI-2015 consists of 13 individual components. HEI-2015 scores have a possible range of 0-100, with higher numbers indicating better diet quality.
Baseline; Immediate post-intervention (approx. 12 weeks)
Diet Quality: Veggie Meter Score
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Skin carotenoid level was measured using a Veggie Meter optical skin scanner, which uses Raman Spectroscopy. The Veggie Meter assesses frequency changes in reflected light to calculate carotenoid presence in the skin and has been validated as a non-self-report, non-invasive measure associated with serum carotenoid levels and self-report measures of fruit and vegetable consumption. Each participant's index finger was scanned three times and the mean of the three measures was recorded for use in data analysis. Veggie Meter scores have a possible range of 0-800, with higher scores indicating better diet quality.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Body Mass Index (BMI)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Participant height (without shoes) was collected using a stadiometer and participant weight (without shoes) was collected using a calibrated digital scale. Height and weight were used to compute a continuous measure of BMI (kilograms per square meter).
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Systolic Blood Pressure (SBP)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height. Two blood pressure measurements were taken, waiting at least one minute between readings. If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken. The mean of the two (or four) measurements was recorded and used in analysis.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diastolic Blood Pressure (DBP)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height. Two blood pressure measurements were taken, waiting at least one minute between readings. If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken. The mean of the two (or four) measurements was recorded and used in analysis.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Total Cholesterol
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
High-Density Lipoproteins (HDL)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Low-Density Lipoproteins (LDL)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Triglycerides
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Glucose
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect random (non-fasting) blood glucose.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diabetes Self-Efficacy (DMSES)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
The Diabetes Management Self-Efficacy Scale (DMSES) was used to measure patient's confidence in managing their diabetes. The DMSES assesses self-reported confidence in managing multiple aspects of their diabetes. The item reponses range from 1 (not at all confident) to 10 (totally confident) and are averaged to generate composite scores, with higher scores indicating higher levels of self-efficacy.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diabetes-Related Distress (PAID-5)
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
The Problem Areas in Diabetes scale (PAID-5) was used to measure diabetes-related distress. The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed. Item responses range from 0 (not a problem) to 4 (serious problem) and are summed to produce an overall composite score, with a total score of 8 or higher indicating possible diabetes-related emotional distress.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Food Insecurity
Periodo de tiempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Food insecurity was assessed using the 2-item Hunger Vital Sign. Affirmative answers ("Often True" or "Sometimes True") to either of the 2 screener items indicates food insecurity. Food insecurity was treated as a binary outcome (0=food secure, 1=food insecure).
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Pearl A McElfish, PhD, University of Arkansas

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de octubre de 2021

Finalización primaria (Actual)

6 de febrero de 2025

Finalización del estudio (Actual)

18 de diciembre de 2025

Fechas de registro del estudio

Enviado por primera vez

30 de abril de 2021

Primero enviado que cumplió con los criterios de control de calidad

5 de mayo de 2021

Publicado por primera vez (Actual)

6 de mayo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • 261074
  • 5R01NR019487 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir